Globe Life Inc.
GLFinancial Snapshot
ticker: GL step: 04 generated: 2026-05-13 source: quick-research
Globe Life Inc. (GL) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $5.227B | $5.448B | $5.778B | +6.1% |
| Net Income | $970.8M | $1,070.8M | $1,071.1M | +0.03% |
| EPS (diluted) | $10.07 | $11.94 | $12.28 | +2.8% |
| Net Operating EPS | — | $12.37 | ~$13.50 | — |
FY2025: Revenue ~$5.99B (+3.7%); net income $1.16B; EPS $14.07 (+14.6%); net operating EPS $14.52. Strong recovery driven by: (1) AIL life net sales +22%; (2) health net sales +71% in some quarters; (3) post-COVID mortality normalization improving life underwriting margins; (4) $685M in share buybacks reducing share count. Q2 2025: adj EPS $3.27 (+10% YoY). Life premiums accounted for 78% of insurance underwriting margin. April 2024 short-seller attack caused temporary ~53% stock decline; SEC closed investigation with no enforcement action; DOJ probe into AIL sales tactics remains ongoing.
Cash Flow & Balance Sheet
| Metric | Value |
|---|---|
| Share Buybacks | $685M (FY2025) |
| Forward P/E | ~10.69x (undervalued vs. sector avg ~10.42x) |
| PEG Ratio | ~0.55 (significantly below 1.0) |
| Health Underwriting Margin | 25% of premium (down from 29%) |
| Direct-to-Consumer | Declining (-8% projected) |
Globe Life's valuation is significantly discounted vs. peers due to the ongoing DOJ probe and 2024 fraud allegation overhang. A forward P/E of ~10.69x and PEG of 0.55 imply the market is pricing meaningful legal risk. If the DOJ probe resolves without major penalties (as the SEC probe did), the discount could narrow significantly toward the sector average of 13–15x P/E.
Key Ratios (approximate)
- P/E: ~10–11x (forward); PEG: 0.55
- Revenue Growth (FY2025): +3.7%; Net income growth: +8.3%
- EPS Growth (FY2025): +14.6% (helped by buybacks reducing share count)
- Net margin: ~19.4% (FY2025)
Growth Profile
Globe Life is a slow-and-steady insurer that grows via premium rate increases, new policy sales through captive agents, and EPS amplification through buybacks. Revenue grew from $5.23B (FY2022) to $5.99B (FY2025) — 1.15x in 3 years. EPS grew faster ($10.07 → $14.07) as buybacks reduced shares outstanding and mortality normalized post-COVID. AIL is the growth engine (+22% life net sales), while direct-to-consumer is a secular drag. Health insurance is a growth opportunity — health net sales +71% in high-activity quarters.
Forward Estimates
- FY2026: Net operating EPS ~$14.45 (CFRA estimate); consensus ~$14–15
- Analyst consensus PT: $163.85 (13 analysts; 11 of 13 = Buy)
- 19% implied upside from recent prices (~$138)
- CFRA upgraded to Buy post-SEC clearance, citing undervaluation + earnings momentum
- Key variable: DOJ probe resolution timeline and penalty risk
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $GL.